Resources

1 Sep, 2020

Stakeholders Push for Further Pull Incentives

With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs and global partners urged...

1 Sep, 2020

Bioversys Bags €17.7m Financing

Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens....

31 Aug, 2020

Pharmaceutical Companies Are Doing Much More Than Battling COVID-19

The merger of Pfizer’s Upjohn business with Mylan NV (NASDAQ: MYL), along with the potential of its COVID-19 vaccine candidate that...

31 Aug, 2020

Stewardship / Resistance Scan

Promise of bacteriophage therapy; New reimbursement models for antibiotics. Paper highlights promise of bacteriophage therapy A new paper in Open...

28 Aug, 2020

This 'Slowly Evolving Crisis' Needs Attention

Hello. I’m Paul Auwaerter with Medscape Infectious Diseases and the Johns Hopkins University School of Medicine. The pandemic and coronavirus...

26 Aug, 2020

Time for a Health Innovation Pact: Rethinking the Design and Delivery of Healthcare

Janssen’s Anouk De Vroey on why we need to extend the public/private partnerships resulting from COVID-19 into more high-level dialogue...

20 Aug, 2020

Secretary Azar Can't Wait to Address Antibiotic Resistance

Late last month, Health and Human Services Secretary Alex Azar extended COVID-19’s status as a public health emergency. But a...

20 Aug, 2020

The Role of Investors in Addressing AMR

Abigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to...

14 Aug, 2020

The Marketplace for New Antibiotics is Fundamentally Broken

One of the mysteries of COVID-19 is why it kills some patients while sparing others with similar health profiles. The...

Loading...
Show More